Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19

Medical Hypotheses
Alexander YangBing Yang

Abstract

The ongoing pandemic of COVID-19 infection demands efforts to reduce spread. In order to eradicate an infectious disease, a method of prevention with low social cost is the most effective way. While we wait for new therapies and a vaccine, we are proposing a solution based on the existing knowledge in biomedical sciences. Here we propose to use low doses of hydroxychloroquine (50-100 mg daily orally) and intranasal interferon alpha-2b (IFN α-2b) spray (0.5 × 106 IU twice daily) for the prophylaxis of COVID-19. Although there are ongoing clinical trials to test the efficacy of hydroxychloroquine for prophylaxis, there has not been any proposal to test the efficacy of IFN α-2b together with hydroxychloroquine to increase protection against COVID-19. Since the two act on two different mechanisms, we strongly believe that the two could have additive effects in prophylaxis against COVID-19. We recommend using a randomized control study to prove efficacy and safety.

Methods Mentioned

BETA
glycosylation

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Related Papers

Australian Journal of General Practice
Heather G Mack
Journal of the American Academy of Dermatology
Muskaan SachdevaRoni P Dodiuk-Gad
Journal of the American Academy of Dermatology
Jane M Grant-Kels
The Lancet Infectious Diseases
Nicola Principi, Susanna Esposito
© 2022 Meta ULC. All rights reserved